Recently, there has been a breakthrough in the treatment of thyroid associated ophthalmopathy (TAO) in China: the first domestically produced IGF-1R targeted drug, cetuximab (N01 injection), has been put into clinical use at Aier Eye Hospital in 16 cities across the country. As the only innovative therapy in China that can reverse the progression of TAO, the launch of this drug not only ends China's long-term dependence on imported targeted drugs, but also brings new hope for "eye retraction and improvement of diplopia" to over 3 million TAO patients in China with a single course cost only 1/15 of imported drugs. Data shows that thyroid related eye disease has become the most common orbital disease worldwide, and patients often face a dual blow of visual impairment and appearance problems due to symptoms such as eye protrusion, eyelid retraction, and diplopia. On the occasion of the International Thyroid Knowledge Promotion Week, experts in orbital diseases at Aier Eye Hospital call for attention to the eye health of thyroid patients, early examination, early detection, and early treatment. According to Professor Yuan Hongfeng, Vice President of Aier Ophthalmology Chongqing Special Zone, trastuzumab can accurately block the IGF-1R signaling pathway, inhibit orbital inflammation and fibrosis, and achieve "drug-induced orbital decompression". Clinical studies have shown that the response rate of sudden eye retraction in the group treated with trastuzumab at 24 weeks was 85.8% (with a retraction of ≥ 2mm), significantly better than the control group. In terms of safety, the incidence of key adverse reactions such as hearing loss is lower than that of foreign original drugs, and most of them are mild to moderate and can be recovered through follow-up. TAO is not a 'single eye disease', but a difficult disease that requires interdisciplinary collaboration. ”Professor Sun Fengyuan, head of the Orbital Oncology Group of Aier Ophthalmology Hospital Group and president of Aier Ophthalmology Sichuan Ophthalmology Hospital, stressed that the incidence rate of thyroid related ophthalmopathy has increased year by year, but it is difficult to treat it. There is a shortage of orbital specialists for this disease, and the diagnosis and treatment plan of the disease is also very complex. All regions should follow the principle of standardized diagnosis and personalized diagnosis and treatment, otherwise it is easy to cause missed diagnosis, misdiagnosis and wrong diagnosis. (New Society)